194 results on '"Bodegård, Johan"'
Search Results
2. Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF)
3. Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
4. Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction
5. Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015
6. Are there lost opportunities in chronic kidney disease? A region-wide cohort study
7. Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD).
8. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
9. Mortality, Healthcare Burden, and Treatment of Chronic Kidney Disease – A Multinational, Observational Study (OPTIMISE-CKD)
10. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study
11. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL
12. Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
13. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
14. Weight change patterns and healthcare costs in patients with newly-diagnosed type-2 diabetes in Sweden
15. Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice
16. Exercise Blood Pressure: The Prognostic Impact of Exercise Systolic Blood Pressure
17. Change in Body Weight and Long-Term Risk of Stroke and Death in Healthy Men
18. Change in Cardiorespiratory Fitness and Risk of Stroke and Death: Long-Term Follow-Up of Healthy Middle-Aged Men
19. Dapagliflozin Initiation and eGFR Trajectories Across uACR Subgroups in Clinical Practice
20. History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case–control study
21. Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting
22. Response by Kosiborod et al to Letters Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”
23. Cross-sectional and longitudinal analyses of the association between lung function and exercise capacity in healthy Norwegian men
24. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013
25. Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
26. Importance of Physical Fitness on Predictive Effect of Body Mass Index and Weight Gain on Incident Atrial Fibrillation in Healthy Middle-Age Men
27. Additional file 1 of Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
28. Implementation of the Convention on Biological Diversity : Lessons from a National Perspective
29. Prevalence, Outcomes, and Cost of CKD in a Contemporary Population of 2·4 Million Patients from 11 Countries: The CaReMe CKD Study
30. History of Heart Failure and Chronic Kidney Disease and the Risk for Allcause Death after COVID-19 During the Three First Waves in Comparison to Influenza Outbreaks in Sweden
31. Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
32. The Oslo Ischaemia Study: cohort profile
33. Novel insights into stroke risk beyond resting and maximal bicycle exercise systolic blood pressure
34. Additional file 1 of Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
35. Cardiorenal Disease is the Costliest CVD in Type 2 Diabetes: A Large Long-Term Observational Study
36. Cardiorenal disease is the most frequent cardiovascular manifestation in type 2 diabetes and associated with increased cardiovascular death: a large observational study in England
37. Lower heart failure and chronic kidney disease risks associated with sodium‐glucose cotransporter‐2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases
38. MORTALITY, CLINICAL EVENTS AND HEALTHCARE COSTS AFTER A FIRST HOSPITALIZATION FOR HEART FAILURE: INSIGHTS FROM EVOLUTION HF
39. Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
40. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
41. Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden : a nationwide observational study
42. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial : A nationwide observational study
43. Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study
44. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
45. Change in Cardiorespiratory Fitness and Risk of Stroke and Death
46. Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies : Real or Bias? Diabetes Care 2018;41:6–10
47. Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study.
48. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsClinical Perspective: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
49. SGLT-2 Inhibitors and Cardiovascular Risk
50. Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.